Mortality in schizophrenia.
Abstract
PURPOSE: The purpose of this article is to describe the current status of knowledge on excess mortality in schizophrenia and its causative factors, and to expand upon previous work evaluating approaches that may reduce mortality rates. METHODS: Literature available since 1995 was identified in a computerized search of the bibliographical databases Medline and Embase, using the topics 'mortality' and 'schizophrenia', and in a cross-reference search for articles that were particularly relevant. RESULTS: Schizophrenia is associated with mortality rates that are two to three times higher than those expected or observed in the general population. This excess of mortality is accounted for by a combination of an increased risk of suicide, in particular in young male patients soon after diagnosis, and more importantly, a higher number of natural deaths. In order to diminish the level of suicide among people with schizophrenia, the majority of research has focused on the identification of risk factors that predispose patients to attempt or commit suicide, while unhealthy styles, polypharmacy and inadequate healthcare have been shown to contribute to the high natural mortality. The link between the use of antipychotics and mortality has not been yet clarified. CONCLUSION: Dramatically increased mortality of schizophrenia patients is well established. It is time to move beyond this topic, and work towards interventions that aim at reducing the mortality risk in such patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Long-term antipsychotic use and adverse lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations.
“Long-term antipsychotic use and adverse lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [3], [19], [20], [22], [31]–[33]”
From Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London (2011) · cites this paper as [19]
Cites
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698 · see citing works
The Disease Burden Associated With Overweight and Obesity
Must, A. (1999) · JAMA · doi:10.1001/jama.282.16.1523 · Cited by 4,804 · see citing works
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · see citing works
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589 · see citing works
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works
Excess mortality of mental disorder
Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.11 · Cited by 1,881 · see citing works
Annual Deaths Attributable to Obesity in the United States
Allison, D. B. (1999) · JAMA · doi:10.1001/jama.282.16.1530 · Cited by 1,868 · see citing works
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554 · see citing works
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475 · cited 1× · see citing works
“The syndrome has been associated with an increased risk for cardiovascular morbidity and mortality.(25,26) Patients with schizophrenia would seem to have a two-fold higher relative risk of developing coronary heart disease (CHD) compared with the general population.”
BackgroundDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428 · see citing works
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · see citing works
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220 · see citing works
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., LAUGHREN, T. P., & Katz, R. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204 · see citing works
Causes of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087 · see citing works
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070 · see citing works
The Lifetime Risk of Suicide in Schizophrenia: A Reexamination
Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.3.247 · Cited by 1,026 · see citing works
The unhealthy lifestyle of people with schizophrenia
Brown, S., Birtwistle, J., ROE, L., & THOMPSON, C. (1999) · Psychological Medicine · doi:10.1017/s0033291798008186 · Cited by 877 · see citing works
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869 · see citing works
Schizophrenia and suicide: Systematic review of risk factors
Hawton, K. E., Sutton, L., Haw, C., Sinclair, J., & Deeks, J. J. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.1.9 · Cited by 777 · see citing works
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423363.45859 · Cited by 733 · see citing works
Mortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679 · see citing works
Mental Disorders and Use of Cardiovascular Procedures After Myocardial Infarction
Druss, B. G. (2000) · JAMA · doi:10.1001/jama.283.4.506 · Cited by 533 · see citing works
Schizophrenics Kill Themselves Too: A Review of Risk Factors for Suicide
Caldwell, C. B., & Gottesman, I. I. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.571 · Cited by 511 · see citing works
Troiano, R. P., Frongillo, E. A., Sobal, J., & Levitsky, D. A. (1996) · PubMed · Cited by 472 · see citing works
Antipsychotics and the Risk of Sudden Cardiac Death
Ray, W. A., Meredith, S. K., Thapa, P. B., Meador, K. G., Hall, K., & Murray, K. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.12.1161 · Cited by 430 · see citing works
Mortality and Causes of Death in First Admitted Schizophrenic Patients
Mortensen, P. B., & Juel, K. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.2.183 · Cited by 412 · see citing works
Practice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors
(2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423363.56008 · Cited by 405 · see citing works
Schizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395 · see citing works
The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia
Allison, D. B., Fontaine, K. R., Heo, M., Mentore, J. L., Cappelleri, J. C., Chandler, L. P., Weiden, P. J., & Cheskin, L. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0402 · Cited by 390 · see citing works
Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course?
McGlashan, T. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00084-0 · Cited by 373 · see citing works
Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study*
Newman, S. C., & Bland, R. C. (1991) · The Canadian Journal of Psychiatry · doi:10.1177/070674379103600401 · Cited by 372 · see citing works
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 356 · see citing works
Suicidal Behavior in Patients With Schizophrenia and Other Psychotic Disorders
Radomsky, E. D., Haas, G. L., Mann, J. J., & Sweeney, J. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1590 · Cited by 349 · see citing works
Mental disorders and cause-specific mortality
Joukamaa, M., HeliöVaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.498 · Cited by 328 · see citing works
Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders
Fenton, W. S., McGlashan, T. H., Victor, B. J., & Blyler, C. R. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.2.199 · Cited by 325 · see citing works
Medical Morbidity and Mortality in Schizophrenia
GOFF, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., Bierer, M. F., Duckworth, K. S., & Sacks, F. M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0205 · Cited by 312 · see citing works
Predisposition to Addiction: Pharmacokinetics, Pharmacodynamics, and Brain Circuitry
Kalivas, P. W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.1 · Cited by 301 · see citing works
A placebo controlled trial of bupropion for smoking cessation in schizophrenia
George, T. P., Vessicchio, J. C., Termine, A., Bregartner, T. A., Feingold, A., Rounsaville, B. J., & Kosten, T. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01339-2 · Cited by 290 · see citing works
Schizophrenia and Substance Abuse
Smith, J. E., & Hucker, S. J. (1994) · The British Journal of Psychiatry · doi:10.1192/bjp.165.1.13 · Cited by 271 · see citing works
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 268 · see citing works
Early Detection of the First Episode of Schizophrenia and Suicidal Behavior
Melle, I. S., Johannesen, J. O., Friis, S., Haahr, U., Joa, I., Larsen, T. K., Opjordsmoen, S., Rund, B. R., Simonsen, E. H., Vaglum, P., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.800 · Cited by 249 · see citing works
Bodyweight Gain with Atypical Antipsychotics
Wetterling, T. (2001) · Drug Safety · doi:10.2165/00002018-200124010-00005 · Cited by 231 · see citing works
Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study
Osby, U. (2000) · BMJ · doi:10.1136/bmj.321.7259.483 · Cited by 220 · see citing works
QTc interval prolongation and antipsychotic drug treatments: focus on sertindole
Lindström, E., Farde, L., Eberhard, J., & Haverkamp, W. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005250 · Cited by 207 · see citing works
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110073920 · Cited by 191 · see citing works
Stahl, S. M., & Grady, M. J. W. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043456070 · Cited by 186 · see citing works
CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia
Paris, J., Bland, R. C., Goldbloom, D. S., Grof, P., LESAGE, A. D., Streiner, D. L., Addington, D. E., Arboleda‐Flórez, J., Benkelfat, C., Bond, M., et al. (2005) · Cited by 184 · see citing works
Cause-specific mortality in psychiatric patients after deinstitutionalisation
Hansen, V., Jacobsen, B. K., & Arnesen, E. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.5.438 · Cited by 149 · see citing works
Kendrick, T. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.6.733 · Cited by 145 · see citing works
Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0701 · Cited by 144 · see citing works
Mortality and causes of death in schizophrenic patients in Denmark
Mortensen, P. B., & Juel, K. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05466.x · Cited by 138 · see citing works
High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia
Hägg, S., Lindblom, Y., Mjörndal, T., & Adolfsson, R. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000188215.84784.17 · Cited by 138 · see citing works
Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription
Ito, H., Koyama, A., & Higuchi, T. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.3.243 · Cited by 133 · see citing works
Centorrino, F., Baldessarini, R. J., Kando, J. C., Frankenburg, F. R., Volpicelli, S. A., & Flood, J. G. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00006 · Cited by 131 · see citing works
Prolongation of QT Interval in Isolated Feline Hearts by Antipsychotic Drugs
Drici, M., Wang, W. X., Liu, X., Woosley, R. L., & Flockhart, D. A. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00011 · Cited by 131 · see citing works
Schizophrenia and Deliberate Self‐Harm: A Systematic Review of Risk Factors
Haw, C., Hawton, K. E., Sutton, L., Sinclair, J., & Deeks, J. J. (2005) · Suicide and Life-Threatening Behavior · doi:10.1521/suli.35.1.50.59260 · Cited by 127 · see citing works
Prevalence of Obesity in Patients Receiving Depot Antipsychotics
Silverstone, T., Smith, G., & Goodall, E. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.2.214 · Cited by 125 · see citing works
Case register study of suicide risk in mental disorders
Baxter, D. N., & Appleby, L. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.4.322 · Cited by 117 · see citing works
Suicidal behaviour in early psychosis
Addington, J., Williams, J. L., Young, J. A., & Addington, D. E. (2004) · Acta Psychiatrica Scandinavica · doi:10.1046/j.0001-690x.2003.00232.x · Cited by 113 · see citing works
Mortality among patients with schizophrenia and reduced psychiatric hospital care
Heilä, H., Haukka, J. K., Suvisaari, J., & Lönnqvist, J. K. (2005) · Psychological Medicine · doi:10.1017/s0033291704004118 · Cited by 109 · see citing works
Attempted suicide in chronic schizophrenia
Roy, A., Mazonson, A., & Pickar, D. (1984) · The British Journal of Psychiatry · doi:10.1192/bjp.144.3.303 · Cited by 101 · see citing works
We Can Talk: Individual Psychotherapy for Schizophrenia
Fenton, W. S. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1493 · Cited by 101 · see citing works
Suicidal indicators in schizophrenia
Dassori, A. M., Mezzich, J. E., & Keshavan, M. S. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05472.x · Cited by 73 · see citing works
Montout, C., Casadebaig, F., Lagnaoui, R., Verdoux, H., Philippe, A., Bégaud, B., & Moore, N. D. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00325-5 · Cited by 69 · see citing works
A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics
Wilkinson, G., & Bacon, N. A. (1984) · Psychological Medicine · doi:10.1017/s0033291700019863 · Cited by 68 · see citing works
Cardiovascular Procedures in Patients With Mental Disorders
Young, J. K., & Foster, D. A. (2000) · JAMA · doi:10.1001/jama.283.24.3198-c · Cited by 65 · see citing works
Suicide in Schizophrenia, Clozapine, and Adoption of Evidence-Based Medicine
Meltzer, H. Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0417 · Cited by 63 · see citing works
The Distribution of Adipose Tissue in Female In-patients Receiving Psychotropic Drugs
STEDMAN, T. J., & Welham, J. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.162.2.249 · Cited by 56 · see citing works
Mortality in chronic schizophrenia during decreasing number of psychiatric beds in Finland
Salokangas, R. K. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00281-x · Cited by 55 · see citing works
[Mortality in schizophrenic patients. 3 years follow-up of a cohort].
Casadebaig, F., & Philippe, A. (1999) · PubMed · Cited by 46 · see citing works
Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore
Sim, K., Su, A., Chan, Y. H., Shinfuku, N., Kua, E. H., & Tan, C. H. (2004) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01239.x · Cited by 32 · see citing works
Épidémiologie des troubles schizophréniques
Hautecouverture, S., Limosin, F., & Rouillon, F. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74620-6 · Cited by 27 · see citing works
Cardiovascular Effects of Novel Antipsychotic Medications
Feinstein, R. E. (2002) · Heart Disease · doi:10.1097/00132580-200205000-00009 · Cited by 27 · see citing works
Dombrovski, A. Y., & Rosenstock, J. B. (2004) · Current Opinion in Psychiatry · doi:10.1097/00001504-200411000-00018 · Cited by 25 · see citing works
Antipsychotics and sudden death: Is thioridazine the only bad actor?
Ray, W. A., & Meador, K. G. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.6.483 · Cited by 24 · see citing works
Screening Mammography in Elderly Women—Reply
Kerlikowske, K. M. (2000) · JAMA · doi:10.1001/jama.283.24.3198 · Cited by 19 · see citing works
The Economics of Treating Obesity
Hutton, J. (1994) · PharmacoEconomics · doi:10.2165/00019053-199400051-00014 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,031 · see citing works
“Age-standardized mortality rates among persons with schizophrenia are approximately double that of the general population and their lifespan is abbreviated by approximately 15–20 years (Parks et al., 2006; Auquier et al., 2007).”
Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714 · see citing works
“Preliminary strategies for preventing premature deaths among people with SMI have been suggested, emphasizing the management of suicide risk and physical illness, minimum polypharmacy, and improvement of accessibility to physical health care [19].”
BackgroundBarnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397 · see citing works
Schizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395 · see citing works
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 357 · see citing works
“There are conflicting data on the question of whether combined antipsychotics may contribute to the excess mortality from natural causes in middle-aged patients with schizophrenia (Auquier et al., 2006; Baandrup et al., 2010; Joukamaa et al., 2006; Waddington et al., 1998).”
BackgroundIs schizophrenia a syndrome of accelerated aging?
Kirkpatrick, B., Messias, E., Harvey, P. D., Fernandez-Egea, E., & Bowie, C. R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm140 · Cited by 335 · see citing works
Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.018 · Cited by 333 · see citing works
Laursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C., & Mortensen, P. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.61 · Cited by 271 · see citing works
The epidemiology of excess mortality in people with mental illness
Lawrence, D., Kisely, S., & Pais, J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005501202 · Cited by 258 · see citing works
Chang, C.-K., Hayes, R. D., Broadbent, M., Fernandes, A. C., Lee, W., Hotopf, M., & Stewart, R. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-77 · Cited by 258 · see citing works
“Preliminary strategies for preventing premature deaths among people with SMI have been proposed, including the management of suicide risk and physical illness, minimizing polypharmacy, and improving accessibility to physical health care [1].”
BackgroundCallaghan, R. C., Veldhuizen, S., Jeysingh, T., Orlan, C., Graham, C., Kakouris, G., Remington, G., & Gatley, J. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.09.014 · Cited by 255 · see citing works
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.017 · Cited by 251 · see citing works
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · see citing works
Smoking, nicotine and neuropsychiatric disorders
Döme, P., Lazáry, J., Kalapos, M. P., & Rihmer, Z. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.013 · Cited by 215 · see citing works
The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities
Carpenter, W. T., & Koenig, J. I. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301639 · Cited by 210 · see citing works
“Reduction in life span is great, and expected to worsen with increased exposure to pharmacological adverse effects (Hennekens et al, 2005; Auquier et al, 2006; Seeman, 2007; Colton and Manderscheid, 2006; Newcomer and Hennekens, 2007).”
BackgroundSafety and tolerability of antipsychotic polypharmacy
Gallego, J. A., Nielsen, J., Binder, M. D., Kane, J. M., & Correll, C. U. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.683523 · Cited by 205 · see citing works
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia
Fleischhacker, W. W., & Uchida, H. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000399 · Cited by 177 · see citing works
“…prospective study that included a cohort of 88 in-patients with schizophrenia in Ireland demonstrated that 39 of the 88 patients died; the maximum number of antipsychotics given concurrently for each individual predicted reduced survival (RR 2.46, 95% CI 1.10–5.47, p=0.03 ; Waddington et al. 1998).”
BackgroundInfluentialCigarette smoking and mortality risk in people with schizophrenia
Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., Warren, K. R., Feldman, S., Shim, J.-C., Love, R. C., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp152 · Cited by 158 · see citing works
“Nevertheless, the high rates of metabolic syndrome and related consequences among people with schizophrenia suggest the importance of preventing and treating obesity, diabetes, lipid disorders, and hypertension in order to decrease morbidity and mortality.(10,16,17) (1)To whom correspondence should be addressed; Maryl…”
BackgroundAntipsychotic medication and cognitive function in schizophrenia
Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.05.004 · Cited by 143 · see citing works
Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment
Harvey, P. D., Strassnig, M., & Silberstein, J. (2019) · Journal of Experimental Psychopathology · doi:10.1177/2043808719865693 · Cited by 141 · see citing works
“Poor physical health and associated comorbid chronic conditions primarily lead to the disease’s life-shortening course (Auquier et al., 2006).”
BackgroundCompleted suicide in schizophrenia: Evidence from a case-control study
Pompili, M., Lester, D., Grispini, A., Innamorati, M., Calandro, F., Iliceto, P., Pisa, E. D., Tatarelli, R., & Girardi, P. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.03.018 · Cited by 138 · see citing works
“Poor adherence to medications was also predictive of completed suicide in our sample of schizophrenia patients, a finding consistent with the current literature (Auquier et al., 2007).”
ResultPolypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription
Ito, H., Koyama, A., & Higuchi, T. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.3.243 · Cited by 133 · see citing works
Schoepf, D., Uppal, H., Potluri, R., & Heun, R. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0436-x · Cited by 131 · see citing works
“is likely that clinicians hesitate to recommend changes in health-related behaviour with respect to prevention of weight gain and obesity as well as of tobacco use, because of the concern that lifestyle modification will prompt relapse of psychiatric symptoms [10].”
BackgroundHayes, R. D., Downs, J. M., Chang, C., Jackson, R., Shetty, H., Broadbent, M., Hotopf, M. H., & Stewart, R. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu120 · Cited by 129 · see citing works
Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia
Baandrup, L., Gasse, C., Jensen, V. D., Glenthoj, B. Y., Nordentoft, M., Lublin, H., Fink‐Jensen, A., Lindhardt, A., & Mortensen, P. B. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04818yel · Cited by 126 · see citing works
Dying Too Soon: Excess Mortality in Severe Mental Illness
de Mooij, L. D., Kikkert, M., Theunissen, J., Beekman, A. T. F., de Haan, L., Duurkoop, P. W. R. A., Van, H. L., & Dekker, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00855 · Cited by 123 · see citing works
“2 are the main physical illnesses in patients with SMI, followed by cancer and infectious diseases (15, 20, 21, 24, 25).”
BackgroundResultRethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes
Lin, P., & Shuldiner, A. R. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.022 · Cited by 114 · see citing works
“, SCZ, schizoaffective disorder, and schizophreniform disorder) (Newcomer, 2007; Auquier et al., 2007).”
Verhaeghe, N., Maeseneer, J. D., Maes, L., Heeringen, C. V., & Annemans, L. (2011) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-8-28 · Cited by 109 · see citing works
“Respiratory disease, CVD and cancer are important causes of this premature mortality in addition to suicide [36-38].”
BackgroundBinder, M. D., Correll, C. U., & Cohen, D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.029 · Cited by 104 · see citing works
Factors predictive of ten-year mortality in severe anorexia nervosa patients
Huas, C., Caille, A., Godart, N. T., Foulon, C., Pham‐Scottez, A., Divac, S. M., Dechartres, A., Lavoisy, G., Guelfi, J., Rouillon, F., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01627.x · Cited by 107 · see citing works
Chan, J., & Sweeting, M. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106071334 · Cited by 101 · see citing works
Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
Correll, C. U., Shaikh, L., Gallego, J. A., Nachbar, J., Olshanskiy, V., Kishimoto, T., & Kane, J. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.02.016 · Cited by 95 · see citing works
Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?
Wildgust, H. J., & Beary, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810384639 · Cited by 93 · see citing works
Serious mental illness and medical comorbidities: Findings from an integrated health care system
Bahorik, A. L., Satre, D. D., Kline‐Simon, A. H., Weisner, C. M., & Campbell, C. I. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.07.004 · Cited by 93 · see citing works
Five-year mortality in a cohort of people with schizophrenia in Ethiopia
Teferra, S., Shibre, T., Fekadu, A., Medhin, G., Wakwoya, A., Alem, A., Kullgren, G., & Jacobsson, L. H. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-165 · Cited by 92 · see citing works
“Factors contributing to premature death in people with schizophrenia include suicide, untreated somatic conditions, and adverse effects of psychotropic medications to mention a few [10].”
BackgroundCardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With Clozapine
Kelly, D. L., McMahon, R. P., Liu, F., Love, R. C., Wehring, H. J., Shim, J.-C., Warren, K. R., & Conley, R. R. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04718yel · Cited by 90 · see citing works
Schoepf, D., Potluri, R., Uppal, H., Natalwala, A., Narendran, P., & Heun, R. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.009 · Cited by 89 · see citing works
“Interestingly, the majority of patients with schizophrenia were middle-aged and therefore may have survived the period of greatest excess mortality associated with suicide [4].”
BackgroundLiu, Y., Li, Z., Zhang, M., Deng, Y., Yi, Z., & Shi, T. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-s1-s17 · Cited by 86 · see citing works
“, SCZ, schizoaffective disorder, and schizophreniform disorder) [50,51].”
Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007) · Pharmacy World & Science · doi:10.1007/s11096-006-9063-1 · Cited by 81 · see citing works
Clozapine for the treatment of schizophrenia
Fakra, É., & Azorin, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.709235 · Cited by 81 · see citing works
“The excess in mortality is accounted for by a combination of an increased risk of suicide as well as a higher number of natural deaths [5].”
BackgroundGrigoletti, L., Perini, G., Rossi, A., Biggeri, A., Barbui, C., Tansella, M., & Amaddeo, F. (2009) · Psychological Medicine · doi:10.1017/s0033291709005790 · Cited by 80 · see citing works
Beary, M., Hodgson, R., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440512 · Cited by 79 · see citing works
Ruiz, J. S., García, J. B., Ruiloba, J. V., Ubago, J. G., & González, M. P. G.-P. (2008) · Actas Españolas de Psiquiatría · Cited by 74 · see citing works
Guideline-Concordant Antipsychotic Use and Mortality in Schizophrenia
Cullen, B., McGinty, E. E., Zhang, Y., dosReis, S., Steinwachs, D. M., Güallar, E., & Daumit, G. L. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs097 · Cited by 73 · see citing works
Mortality in people with depressive, anxiety and alcohol use disorders in Finland
Markkula, N., Härkänen, T., Perälä, J., Partti, K., Peña, S., Koskinen, S. V. P., Lönnqvist, J. K., Suvisaari, J., & Saarni, S. I. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.094904 · Cited by 70 · see citing works
“3,4,25,26 For instance, a large register-based study in Denmark showed high standardised mortality ratios for all 11 categories of mental disorders that were investigated.”
de León, J., Greenlee, B., Barber, J. W., Sabaawi, M., & Singh, N. N. (2008) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2008.10.010 · Cited by 68 · see citing works
Functional Status and All-Cause Mortality in Serious Mental Illness
Hayes, R. D., Chang, C., Fernandes, A. C., Begum, A., To, D., Broadbent, M. T. M., Hotopf, M. H., & Stewart, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044613 · Cited by 69 · see citing works
“[12,13,14,15,16] It is possible that adverse interpersonal and lifestyle factors may contribute to the observed excess mortality [6,17,18,19].”
BackgroundInfluentialTHARA, R., & Kamath, S. (2015) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.161487 · Cited by 68 · see citing works
“[4] Auquier et al ., [11] however, report more suicides in young males with schizophrenia.”
Thomas, S. H. L., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., Jeunne, C. L., Naber, D., Priori, S., Sturkenboom, M., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01563.x · Cited by 67 · see citing works
An increased risk of stroke among young schizophrenia patients
Lin, H., Hsiao, F., Pfeiffer, S., Hwang, Y., & Lee, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.485 · Cited by 65 · see citing works
Chung, A. K., & Chua, S.-E. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110376685 · Cited by 63 · see citing works
Chacón, F., Mora, F., Gervás-Ríos, A., & Gilaberte, I. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-22 · Cited by 59 · see citing works
“Cardiovascular disease (CVD) is the most common cause of death in patients with SMI [2,29-32], and the statement proposes a series of interventions for the recommended management of CVD risk factors.”
BackgroundExcess mortality and shortened life expectancy in people with major mental illnesses in Taiwan
Pan, Y., Yeh, L., Chan, H., & Chang, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000694 · Cited by 60 · see citing works
“Preliminary strategies for preventing premature deaths had been suggested, emphasising the management of suicide risks and physical illnesses by the improvement of accessibility to health care for comorbid physical illnesses (Auquier et al., 2006).”
BackgroundHow gender affects the pharmacotherapeutic approach to treating psychosis – a systematic review
Lange, B., Mueller, J. K., Leweke, F. M., & Bumb, J. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1288722 · Cited by 58 · see citing works
“The researchers reported sex as an important effect modifier of risk with increased CVD risk in women [75].”
BackgroundInfluentialNew Wine in Old Bottle: Late-Life Psychosis
Iglewicz, A., Meeks, T. W., & Jeste, D. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.02.008 · Cited by 38 · see citing works
Tzeng, N., Hsu, Y., Ho, S., Kuo, Y.-C., Lee, H.-C., Yin, Y.-J., Chen, H.-A., Chen, W., Chu, W. C.-C., & Huang, H.-L. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006777 · Cited by 56 · see citing works
“A higher risk for diabetes mellitus, hyperlipidaemia, obesity and consequent cardiovascular or cerebrovascular diseases has been noted in patients with schizophrenia, along with a higher mortality related to these diseases—as much as two to three times higher in comparison with the general population.(3) However, whet…”
Fok, M. L.-Y., Stewart, R. J., Hayes, R. D., & Moran, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100979 · Cited by 52 · see citing works
“Level of service contact and interventions may have a bearing on symptoms and health [39], either positively or negatively, which can contribute to mortality risk.”
BackgroundPostmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review
Sweeting, J., Duflou, J., & Semsarian, C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.029 · Cited by 50 · see citing works
Rimes, R., Moura, A. D. S., Lamego, M. K., Filho, A. S. S., Manochio, J., Paes, F., Carta, M. G., Mura, G., Wegner, M., Budde, H., et al. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666151111130659 · Cited by 53 · see citing works
“expression) and IGF-1 levels in hippocampus and cerebral cortex [53,54], while human”
Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 52 · see citing works
Mortality among persons with schizophrenia in Sweden: An epidemiological study
Fors, B. M., Isacson, D. G. L., Bingefors, K., & Widerlöv, B. (2007) · Nordic Journal of Psychiatry · doi:10.1080/08039480701414932 · Cited by 48 · see citing works
Antipsychotic polypharmacy: review of mechanisms, mortality and management
Langan, J., & Shajahan, P. M. (2010) · The Psychiatrist · doi:10.1192/pb.bp.108.024257 · Cited by 48 · see citing works
Refining and integrating schizophrenia pathophysiology – Relevance of the allostatic load concept
Misiak, B., Frydecka, D., Zawadzki, M., Krefft, M., & Kiejna, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.06.004 · Cited by 47 · see citing works
Clinical factors related to schizophrenia relapse
Porcelli, S., Bianchini, O., de Girolamo, G., Aguglia, E., Crea, L., & Serretti, A. (2016) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2016.1149195 · Cited by 47 · see citing works
“…unclear how the metabolic side effects of SGAs impact on the morbidity and mortality of patients in the long term, as well as FGAs side effects (Auquier et al. 2006) Concerning the differences between the two classes of antipsychotics in terms of efficacy, literature data were less conclusive.”
BackgroundKadra-Scalzo, G., Stewart, R. J., Shetty, H., MacCabe, J. H., Chang, C., Taylor, D. M., & Hayes, R. D. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12906 · Cited by 45 · see citing works
“Patients with serious mental illnesses (SMI) have been estimated to die approximately 15 to 20 years earlier than the general population (1, 2).”
BackgroundKim, S., Kim, S., Mun, J.-W., Bae, K., Kim, J., Kim, S., Yang, S.-J., Shin, I., & Yoon, J. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.2.79 · Cited by 45 · see citing works
Influences on uptake of cancer screening in mental health service users: a qualitative study
Clifton, A., Burgess, C. C., Clement, S., Ohlsen, R. I., Ramluggun, P., Sturt, J. A., Walters, P., & Barley, E. A. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1505-4 · Cited by 46 · see citing works
“Lifestyle factors such as smoking, obesity, alcohol use, poor diet and lack of exercise in service users are likely to increase morbidity and mortality [3–10], however it is likely that there are other contributing factors [3], such as low uptake by service users of cancer screening tests offered nationally [11, 12] l…”
BackgroundGenetic Determinants of Clozapine-Induced Metabolic Side Effects
Vasudev, K., Choi, Y., Norman, R. M. G., Kim, R. B., & Schwarz, U. I. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716670128 · Cited by 45 · see citing works
“Schizophrenia is a severe mental illness and is associated with mortality rates 2 to 3 times higher than the general population.(1) Schizophrenia has been reported as an independent risk factor for metabolic syndrome, including insulin resistance and increased visceral adiposity.”
BackgroundFactors associated with antipsychotic dosing in psychiatric inpatients: a prospective study
Barbui, C., Biancosino, B., Esposito, E., Marmai, L., Donà, S., & Grassi, L. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3281084ea8 · Cited by 45 · see citing works
“Persistent exposure to high AP doses might additionally contribute to explain the high mortality rate observed in psychiatric patients (Waddington et al., 1998; Joukamaa et al., 2006).”
BackgroundValimaki, M. A., Hätönen, H. M., Lahti, M., Kuosmanen, L., & Adams, C. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007198.pub2 · Cited by 42 · see citing works
Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms
Abdelmawla, N., & Mitchell, A. J. (2006) · Advances in Psychiatric Treatment · doi:10.1192/apt.12.1.35 · Cited by 43 · see citing works
Maas, U., & Strubelt, S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.02.050 · Cited by 42 · see citing works
Mortality and tardive dyskinesia: long-term study using the US National Death Index
Dean, C. E., & THURAS, P. D. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.049395 · Cited by 42 · see citing works
The thalamus in psychosis spectrum disorder
Anticevic, A., & Halassa, M. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1163600 · Cited by 44 · see citing works
“Cognitive control deficits are a major focus for research and treatment development, as they are relatively unaffected by current medications and contribute to overall morbidity and loss of workforce by the illness (Auquier et al., 2006; Kooyman et al., 2007).”
BackgroundExtended-Release Intramuscular Paliperidone Palmitate
Carter, N. J. (2012) · Drugs · doi:10.2165/11208640-000000000-00000 · Cited by 40 · see citing works
Antipsychotic polypharmacy – confusion reigns
Taylor, D. M. (2010) · The Psychiatrist · doi:10.1192/pb.bp.109.027086 · Cited by 40 · see citing works
Assessment and treatment of suicide risk in schizophrenia
Pompili, M., Lester, D., Innamorati, M., Tatarelli, R., & Girardi, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.51 · Cited by 40 · see citing works
Elias, A. N., & Hofflich, H. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.08.036 · Cited by 40 · see citing works
Cannabis, Psychosis, and Mortality: A Cohort Study of 50,373 Swedish Men
Manrique-Garcia, E., de León, A. P., Dalman, C., Andréasson, S., & Allebeck, P. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.14050637 · Cited by 39 · see citing works
Garbett, K. A., Gal-Chis, R., Gaszner, G., Lewis, D. A., & Mirnics, K. (2008) · PubMed · Cited by 38 · see citing works
Suicidality prior to presentation in first‐episode psychosis
Foley, S. R., Jackson, D., McWilliams, S., Renwick, L., Sutton, M., Turner, N., Kinsella, A., & O’Callaghan, E. (2008) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2008.00084.x · Cited by 38 · see citing works
“Suicide and attempted suicide contribute significantly to the increased mortality and morbidity associated with psychotic illness.(1,2) Individuals with psychosis have at least 16-fold increased risk of suicide compared with the general population.”
BackgroundSubsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia
Zisook, S., Montross, L. P., Kasckow, J., Mohamed, S., Palmer, B. W., Patterson, T. L., Golshan, S., Fellows, I. E., Lehman, D., & Solorzano, E. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180a725ec · Cited by 36 · see citing works
Disturbances in White Matter Integrity in the Ultra-High-Risk Psychosis State—A Systematic Review
Waszczuk, K., Rek-Owodziń, K., Tyburski, E. M., Mak, M., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112515 · Cited by 35 · see citing works
“comorbidities: analyses show that schizophrenia patients are at a 2–3 times greater risk of mortality [8,9] and a significantly greater risk of diabetes (15% of patients with schizophrenia compared to 6% in the general population) and metabolic syndrome [10].”
BackgroundMental Illness and Use of Screening Mammography Among Medicaid Beneficiaries
Koroukian, S. M., Bakaki, P. M., Golchin, N., Tyler, C. V., & Loue, S. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.03.002 · Cited by 35 · see citing works
Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization
Rantanen, H., Koivisto, A., Salokangas, R. K. R., Helminen, M., Oja, H., Pirkola, S. P., Wahlbeck, K., & Joukamaa, M. I. (2008) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-008-0414-1 · Cited by 36 · see citing works
“It has been suggested that atypical antipsychotic drugs as well as conventional neuroleptics and antipsychotic polypharmacy contribute to an elevated mortality risk [1, 23, 41, 47, 48, 57].”
BackgroundAlene, M., Wiese, M. D., Angamo, M. T., Bajorek, B. V., Yesuf, E. A., & Wabe, N. T. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-10 · Cited by 34 · see citing works
Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia
Tay, Y. H., Nurjono, M., & Lee, J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.023 · Cited by 34 · see citing works
“Schizophrenia has been associated with increased mortality (Curkendall et al., 2004; Auquier et al., 2006) and a reduction in life expectancy (Hennekens et al., 2005).”
BackgroundManaging Suicidality in Schizophrenia
Mamo, D. C. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/07067437070526s106 · Cited by 32 · see citing works
“population, the excess being accounted for by both suicide and premature natural death.(1) Not surprisingly, this devastat-”
Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention
Abdelmawla, N., & Mitchell, A. J. (2006) · Advances in Psychiatric Treatment · doi:10.1192/apt.12.2.100 · Cited by 31 · see citing works
Development of integrated mental health care: Critical workforce competencies
Delaney, K. R., Robinson, K. M., & Chafetz, L. (2013) · Nursing Outlook · doi:10.1016/j.outlook.2013.03.005 · Cited by 30 · see citing works
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29 · see citing works
Using Patient-facing Kiosks to Support Quality Improvement at Mental Health Clinics
Cohen, A. N., Chinman, M., Hamilton, A. B., Whelan, F., & Young, A. S. (2013) · Medical Care · doi:10.1097/mlr.0b013e31827da859 · Cited by 29 · see citing works
Associations between symptoms and all-cause mortality in individuals with serious mental illness
Hayes, R. D., Chang, C., Fernandes, A. C., Begum, A., To, D., Broadbent, M. T. M., Hotopf, M. H., & Stewart, R. J. (2011) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2011.09.012 · Cited by 28 · see citing works
“In addition there may be deleterious physical consequences of long-term antipsychotic use [26] which we were not able to take into account in this analysis.”
BackgroundMethodNyboe, L., Lemcke, S., Møller, A. V., & Stubbs, B. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112556 · Cited by 28 · see citing works
Pfrimmer, D. M. (2009) · The Journal of Continuing Education in Nursing · doi:10.3928/00220124-20090201-04 · Cited by 28 · see citing works
The Long Non-Coding RNA GOMAFU in Schizophrenia: Function, Disease Risk, and Beyond
Zakutansky, P. M., & Feng, Y. (2022) · Cells · doi:10.3390/cells11121949 · Cited by 27 · see citing works
Weinmann, S., & Aderhold, V. (2009) · Psychosis · doi:10.1080/17522430903501999 · Cited by 27 · see citing works
The QTc interval and its dispersion in patients receiving two atypical antipsychotics
Correll, C. U., Frederickson, A. M., Figen, V., Ginn-Scott, E. J., Moya, R. A. P., Kane, J. M., & Manu, P. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0829-4 · Cited by 25 · see citing works
Rational pharmacotherapy in early psychosis
Remington, G. J. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.48.s77 · Cited by 25 · see citing works
- Authors
- Auquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C.
- Affiliations
- Hôpital de la Timone (FR)
- Hôpital Sainte-Marguerite (FR)
- Centre Hospitalier Sainte-Anne (FR)
- Corresponding author
- Auquier, Pascal
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2006-10-23
- Volume
- 15
- Issue
- 12
- Pages
- 873-879
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2097031522
- Cited by
- 249
- References
- 77
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 7 · 2022: 6 · 2021: 8 · 2020: 5 · 2019: 10 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 11 · 2014: 13 · 2013: 20 · 2012: 27
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacoepidemiology and Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- schizophrenia, excess mortality, suicide risk, natural mortality, risk factors, polypharmacy, antipsychotic drugs, quality of care
- MeSH terms
- Cardiovascular Diseases, Cause of Death, Health Services Accessibility, Humans, Risk, Schizophrenia, Suicide, Antipsychotic Agents, Violence, Harm Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review